Clinical trials: Primary Membranous Nephropathy, open to volunteers
Primary Membranous Nephropathy
Study of YK012 in Primary Membranous Nephropathy
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (PMN).
- Trial name
- NCT06982729
- Testing
- YK012
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Excyte Biopharma Ltd
Primary Membranous Nephropathy
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
- Trial name
- NCT06470191
- Testing
- B007, Cyclosporin Capsules
- Where
- 21 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Primary Membranous Nephropathy
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
This is a multiple-center, prospective, open-label, positive drug controlled, randomized, clinical study to evaluate the safety and efficacy of Telitacicept in the treatment of primary membranous nephropathy.
- Trial name
- TEST-T-PMN (NCT06614985)
- Testing
- Telitacicept, Prednisone, Cyclophosphamide
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Renmin Hospital of Wuhan University
Primary Membranous Nephropathy
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
- Trial name
- AUTUMN (NCT07157787)
- Testing
- ALXN1920
- Where
- 40 sites in United States, Argentina and 8 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Primary Membranous Nephropathy
Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
This is a randomized, open-label, cyclosporine-controlled, multicenter Phase III study. It aims to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of zuberitamab versus cyclosporine in patients with primary…
- Trial name
- NCT07830433
- Testing
- Zuberitamab 1000mg, Cyclosporine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Primary Membranous Nephropathy
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
- Trial name
- NCT07289763
- Testing
- SHR-2173 injection
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Glomerulonephritis, Membranous
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
- Trial name
- MOMENT (NCT07851220)
- Testing
- Inebilizumab, Tacrolimus
- Where
- 4 sites in United States
- Volunteers
- 159 people
- Sponsor
- Amgen
Nephrotic Syndrome, Membranous Nephropathy
Circulating Factors in Nephrotic Syndrome
A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.
- Conditions
- Nephrotic Syndrome, Membranous Nephropathy, Minimal Change Disease, Primary Focal Segmental Glomerulosclerosis
- Trial name
- NCT06315504
- Testing
- Observation
- Volunteers
- 104 people
- Sponsor
- Iain Bressendorff
Membranous Nephropathy, Nephrotic Syndrome
Belimumab With Rituximab for Primary Membranous Nephropathy
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with…
- Trial name
- REBOOT (NCT03949855)
- Testing
- Belimumab, Rituximab
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Membranous Nephropathy
Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy
High-grade proteinuria is one of the key determinants of adverse renal prognosis in patients with primary membranous nephropathy (PMN).The main purpose of this study is to determine whether Rituximab combined with Cyclosporine is…
- Trial name
- NCT07861204
- Testing
- Rituximab combined with cyclosporine, rituximab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking University First Hospital
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Primary Membranous Nephropathy
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
- Trial name
- CLEAR-AbKD (NCT07571746)
- Testing
- Surovatamig
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 43 people
- Sponsor
- AstraZeneca
Membranous Nephropathy
An Outcome Analysis of Primary Membranous Nephropathy
This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.
- Trial name
- PROMENADE (NCT06242327)
- Where
- 2 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Primary Membranous Nephropathy
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
- Trial name
- PrisMN (NCT07096843)
- Testing
- budoprutug
- Where
- 38 sites in United States, Argentina and 5 more
- Volunteers
- 45 people
- Sponsor
- Climb Bio, Inc.
IgA Nephropathy, Membranous Nephropathy
IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients
IM19 CAR-T cell therapy for IgA nephropathy patients with urinary protein and renal dysfunction, as well as patients with intermediate to high-risk primary membranous nephropathy
- Trial name
- NCT06690359
- Testing
- IM19 chimeric antigen receptor T cell injection
- Volunteers
- 12 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Membranous Nephropathy, Nephrotic Syndrome
Clinical Prediction Model for Disease Progression in Primary Membranous Nephropathy
This prospective observational study aims to evaluate predictors of disease progression in patients with primary membranous nephropathy and to assess the performance of a prognostic nomogram in predicting renal outcomes in the…
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome, Kidney Diseases
- Trial name
- NCT07785739
- Volunteers
- 128 people
- Sponsor
- Assiut University
Lupus Nephritis, Primary Membranous Nephropathy
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Trial name
- NCT06557265
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Nkarta, Inc.
Primary Membranous Nephropathy
A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy
This study is a multicenter, randomized, controlled, open-label, Phase Ⅱ clinical study to evaluate the efficacy, safety, Pharmacokinetics characteristics, Pharmacodynamics effects, and immunogenicity of JMT601 in participants…
- Trial name
- NCT07029139
- Testing
- JMT601 Injection, Rituximab, Cyclosporin Capsules
- Volunteers
- 156 people
- Sponsor
- Shanghai JMT-Bio Inc.
Primary Membranous Nephropathy
A Real World Study About PMN
The investigators designed a randomized, controlled, multicenter clinical study to compare the efficacy and safety of rituximab combined with hormones versus rituximab monotherapy in the treatment of primary membranous…
- Trial name
- PMNTRWS (NCT06893328)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wei Chen
Primary Membranous Nephropathy
Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy
This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group.
- Trial name
- NCT05514015
- Testing
- rituximab combined with corticosteroids, rituximab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University